China Pharma Holdings (CPHI) Accounts Payables (2010 - 2026)

China Pharma Holdings has reported Accounts Payables for 17 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 20.48% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (up 20.48% YoY), and the FY2025 full-year result was $2.6 million, up 1038.6% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.6 million, up from $2.6 million in the prior quarter.
• The five-year high for Accounts Payables was $2.6 million in Q1 2026, with the low at $141036.0 in Q2 2024.
• Historically, Accounts Payables has averaged $1.4 million across 5 years, with a median of $1.8 million in 2022.
• Annual changes were most pronounced in 2024 — Accounts Payables tumbled 93.7% — and 2025, when it soared 1038.6%.
• China Pharma Holdings' Accounts Payables stood at $667082.0 in 2022, then jumped by 242.19% to $2.3 million in 2023, then tumbled by 90.14% to $225106.0 in 2024, then soared by 1038.6% to $2.6 million in 2025, then grew by 1.1% to $2.6 million in 2026.
• The last three Accounts Payables figures came in at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $588739.0 (Q3 2025), per Business Quant data.